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ABSTRACT 
 
MEDICATION EXPENDITURE AND RESOURCE UTILIZATION AMONG 
PATIENTS WITH MUSCULOSKELETAL DISORDERS: ANALYSIS OF 2007 
MEDICAL EXPENDITURE PANEL SURVEY 
 
 
By 
Nipun Atreja 
May 2012 
Thesis Supervised by Dr. Khalid M. Kamal 
Objective: To estimate the national prevalence and direct incremental expenditures of 
musculoskeletal disorders (MSD's) using the 2007 Medical Expenditure Panel Survey 
data. 
Methods: A retrospective database analysis was conducted and individuals with MSD's 
(ICD-9-CM codes 274.00; 710.00-738.00) were identified.  Dependent variables were 
total health care and other service category expenditures.  The study utilized descriptive 
and regression analyses. 
Results: In 2007, the national prevalence of MSD's was 33 million with incremental 
costs of $886.49 per person.  The inpatient expenditures ($33,461.85) were the highest 
cost component in MSD’s and the predictors of total health care expenditures were age, 
marital status, and presence of the disease condition.   
 v 
 
 
Conclusion: The systematic assessment of MSD's and their associated incremental costs 
to the society is essential in increasing the awareness of decision makers to implement 
intervention strategies that are effective in lowering the disease incidence and in reducing 
the overall cost of disease management.  
 
Keywords:  Musculoskeletal disorders, Medical Expenditures Panel Survey, incremental 
health care expenditures, retrospective analysis, MSD’s, MEPS. 
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CHAPTER ONE 
INTRODUCTION 
According to the Federal Bureau of Labor Statistics (BLS), musculoskeletal 
disorders (MSD's) include injuries and disorders to muscles, nerves, tendons, ligaments, 
joints, cartilage, and spinal discs.
1
  MSD's do not include injuries resulting from slips, 
trips, falls, or similar accidents.  The term MSD's identifies a large group of conditions 
that result from body trauma and often involves the joint, muscle and bone.  The major 
disorders included under MSD's are diffuse diseases of connective tissue, arthropathies, 
rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), spondylosis, 
polymyalgia rheumatica, disorders of soft tissues, osteomyelitis periostitis, disorders of 
bone and cartilage, and other acquired musculoskeletal deformities. 
 
Epidemiology 
The World Health Organization (WHO) scientific group have projected an 
increase in the burden of MSD's in the developed and developing countries primarily due 
to an increase in the overall life expectancy of the population and the subsequent increase 
in non-communicable diseases.
2
  According to the Bone and Joint Organization 
estimates, by 2030, individuals aged 65 years and older will double in size and the fastest 
growth will be seen in individuals over 85 years of age.
3 
 This in turn would potentially 
result in increased cases of MSD’s in the society. 
 2 
 
 
The prevalence of MSD's in the United States (US) ranged from 27.8% – 30.2% 
between 1997 and 2000.
4
  The incidence of MSDs increased by 16% between 1996-1998 
and 2002-2004 and in 2008, an estimated 110 million adults (approximately 50% of the 
adult population) reported having a disabling musculoskeletal condition.  Currently, one 
in four individuals has a MSD that requires medical attention.
 4 
MSD’s are the leading occupational disease among all work-related illnesses not 
only in the US but also in Nordic countries and Japan.
3
  An estimated 40% of all upper 
extremity disorders in the employed population of the US are due to occupational 
exposure and the prevalence of MSD’s is higher in labor intensive production units such 
as furniture and heavy machinery.
5
  
 
Economic and Humanistic Burden of MSD's 
MSD’s have substantial economic and humanistic impact on the US health care 
system.  The annual direct and indirect costs for the treatment of MSD’s is approximately 
$849 billion, which is around 7.7% of the US Gross Domestic Product (GDP).
3  
Over the 
last decade, there has been two percentage points increase in the population that needs 
medical care for problems related to MSD’s.  This has resulted in a 41% increase in 
direct medical costs associated with MSD's. 
6
 
The direct cost of treatment of MSD’s in 2002-04 was $510 billion (~ 4.6% of US 
GDP).
6 
 Almost 85% of the people affected by the MSD's reported at least one 
ambulatory visit to physician’s office.  In 2002-2004, ambulatory physician visits due to 
 3 
 
 
MSD's were 507.9 million (52%) compared to 425.5 million (40%) in1996-1998.
6
  Due 
to an increase in the number of MSD’s-related visits over the same period, a 69% 
increase in the total non-physician ambulatory visits at a cost of $135.3 million was 
incurred.
6
  Prescription drug utilization is also significant in this population.  The mean 
prescriptions filled per person increased from 13.1 in 1996-1998 to 18.6 in 2002-2004 
resulting in a financial burden of $1.6 billion in 2002-2004.
6
 
The indirect costs of MSD’s in the age group of 18-64 years were $339 billion (~ 
3.1% of the US GDP).  Some of the major factors that contribute to these costs include 
loss in wages due to presenteeism (not functioning to 100% of the work ability), and 
absenteeism (absent from work due to an illness).
6
  Additionally, individuals with MSD’s 
have reportedly decreased the numbers of hours they work, some have changed jobs that 
require less physical activity, while others have completely left working, thereby adding 
to the loss in productivity.
7
 
In addition to the economic impact, MSD’s have a tremendous effect on 
individual’s  quality of life (QoL).3  Compared to gastrointestinal conditions, chronic 
respiratory diseases, and cardiovascular conditions, individuals with MSD's report poorer 
QoL, especially for bodily pain and physical function.
8 
 Musculoskeletal disorders are 
also a major cause of pain in the elderly population and are responsible for functional 
impairment which restricts mobility and  self-care tasks.
9
  MSD’s are one of the most 
common cause of disability in the US.  MSD's cause many long-term physical disabilities 
whose impact sometimes leads to major changes in the life of the people suffering from 
these disorders.  The impact of MSD's on the health-related quality of life (HRQoL) of 
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individuals due to its impact on pain and reduced physical function is also well 
documented.
9
  
 
Pathology, Epidemiology and Management of Major Disorders under MSD’s 
Gout 
Gout is a heterogeneous disease characterized by deposition of monosodium urate 
crystals in the joints and surrounding tissues resulting in severe pain and erythema.
10
  
Depending on the severity of the disorder, gout can be classified into acute and chronic 
gout.  The symptomatic classification of gout is as follows
11
: asymptomatic 
hyperuricemia, acute gouty arthritis, intercritical gout, and chronic tophaceous gout. 
 The prevalence of gout in the US is higher than many countries and the rates 
range from 0.47% to 0.52%.
11
  Elderly individuals, those with transplantation (allograft) 
and renal insufficiency are at an increased risk of developing gout.
12
  The most common 
risk factor associated with gout includes hyperuricemia which is generally triggered by 
the consumption of alcohol and diet rich in purine, drugs such as thiazide diuretics, loop 
diuretics, and cyclosporine also play a role in potentiating the development of 
hyperuricemia.
12
 
 The monitoring of renal uric acid excretion is important for the systematic 
management of gout.  However, the presence of co-morbidities, especially in the acute 
stages of gout complicates the disease management.  The following drugs are commonly 
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used in the treatment of gout: colchicine, NSAIDs (Ketoprofin and Ibuprofen), 
corticosteroids, anakinra, uric acid lowering drugs (allopurinol, xanthine oxidase 
inhibitor), febuxostat (novel drug with more potency), probencid, and pegylated uricase.
10
  
 
Ankylosing Spondylitis   
 Ankylosing Spondylitis (AS) is a chronic disabling arthritic condition 
characterized by severe inflammatory chronic back pain.
13 
 The occurrence of AS is 
strongly associated with the expression of HLA B27genotype and is also triggered by 
microbial infections.  As the disease progresses, the joint pain worsens, and the 
inflammation spreads to eyes, hips, knees, lungs, entire spinal assembly, shoulders, 
tendons and various ligaments attached to bones.
14
  The incidence of AS is estimated at 
0.8 % in adults aged 25 to 49 years.
14
  Males are more susceptible to AS compared to 
females and this disorder also affects young adults between the ages of 20 and 30 years.
14
  
The goal of AS management is to reduce the intensity of inflammation, pain and 
stiffness due to the disease.
14
  The commonly used drugs are NSAIDS, analgesics 
(paracetamol and opioid drugs), disease modifying anti-rheumatic drugs (methotrexate 
and sulfasalazine)
15
 and tumor-necrosis-factor alpha (TNF-α) blockers (etanercept, 
infliximab, adalimubab, and golimubab).
16
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Osteoarthritis  
 Osteoarthritis (OA) is a degenerative joint disorder that mainly affects the 
cartilage cells.  It is considered an acquired degenerative process due to its genetic 
predisposition.  Around, 70- 90% of the geriatric population (75 years and above) have at 
least one joint affected with OA and this condition is considered as the second most 
common form of disability among women and men.  This condition can be managed and 
treated by family physicians but in severe cases, surgery is recommended.  The OA of 
knee and hip are very common with a prevalence of 6% and 3%, respectively in US 
adults.
17
  
A variety of factors such as heredity, age, deposition of urate crystals in the joints, 
occupational markers, high bone mineral density, peripheral neuropathy, obesity and 
trauma are probable risk factors of OA.  Some factors such as severe athletic exercises 
and sports involving torsional impact are also considered as probable risk factors of 
OA.
18
  
The management of OA includes pharmacotherapy, physiotherapy, novel genetic 
engineering techniques and also patient education.  The medications that are 
recommended to relieve the pain are NSAIDs and analgesics.  The alternative medicine 
for OA includes glucosamine sulfate and chondroitin sulfate although their clinical 
effectiveness is yet to be proven.
19 
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Rheumatoid Arthritis 
 
Rheumatoid Arthritis (RA) is a chronic, inflammatory, autoimmune disorder 
which is characterized by severe inflammation in the joints along with swelling, stiffness, 
damage of the cartilage and bone around the infected joint.  There is no complete cure for 
this disease, however, there are a number of disease modifying anti-rheumatic drugs, 
NSAIDS, analgesics, steroids, physical exercises and patient education that are 
recommended in the management of RA.
20
  RA results in permanent damage to the 
affected part or deformity or immobilization accompanied by symptoms like low grade 
fever, fatigue, anemia, pericarditis, myocarditis or pulmonary fibrosis.  This disorder 
affects the individual’s life style and severely compromises their QoL.21  RA affects 
around 1.3 million people in the US with an increase in the disease incidence seen in 
women over the last decade.
21
  
 
Problem Statement 
MSD’s are a major cause of morbidity and health care burden in the US and their 
impact on clinicians, payers, patients, and the society as a whole is pervasive.  In the US, 
MSD’s were reported by 107 million adults in 2005 and were the leading cause of 
disability accounting for more than one-half of all chronic conditions in individuals over 
50 years of age.  Given the high prevalence rates, these conditions have been consistently 
included as leading health indicators in both Healthy People 2010 and 2020.
22
  The 
prevalence of MSD's have been shown to increase markedly with age, and are affected by 
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lifestyle factors, such as obesity and lack of physical activity.  With a projected increase 
in the aging population over the next two decades, coupled with an increasing sedentary 
lifestyle, there is a strong possibility for a dramatic increase in the burden of MSD’s on 
the society.
23 
 The burden of MSD’s in terms of resource utilization and costs to the 
society would thus be staggering.  Current estimates show that MSD’s present a multi-
billion-dollar-a-year burden on the society.
23 
 The per capita medical care expenditures of 
persons with musculoskeletal conditions in 1996 averaged $3,578, amounting to a 
national total expense of $193 billion (~2.5% of US GDP).
24  
By 2006, the medical 
expenditures for MSD's had increased to $950 billion (7.4% of GDP) and this is further 
expected to increase given the expected growth in the aging population.
6
 
 In MSD's, the major direct cost components include hospitalizations, ambulatory 
care, and prescription drugs.  People with MSD’s have 50% higher health care 
expenditures compared to non-MSD’s ($3,578 against $ 2,313).  Out of the total health 
care cost, hospitalization costs accounts for 37% of the cost .
25
  Additionally, indirect 
costs, primarily in the form of lost wages associated with MSD's, contribute substantially 
to the health care burden with an estimated cost of  $373.1 billion in 2006 (~2.9% of US 
GDP).
6
 
Prescription drug cost is another major component of the overall direct medical 
cost, along with the physician and other service provider costs in MSD's.  In the last 
decade, there has been a paradigm shift in the treatment of MSD’s, especially with the 
introduction of biologic therapies in RA and AS.  Biologics are reported to have excellent 
therapeutic efficacy, however, the treatment cost has increased significantly as these 
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classes of drugs are very expensive.
26  
Previous estimates of the burden of MSDs on the 
society have not included the cost impact of these biologics on the total health care costs.  
Thus, there is a gap in the literature on the new treatment cost estimates and the type of 
health care resources that are utilized in MSD’s.  Moreover, it is important to assess the 
cost of treatment of MSD's, especially under different service categories like inpatient, 
outpatient, and prescription drug services.  It would also be of great interest to different 
decision makers such as payers and clinicians to know the incremental costs of MSD's 
compared to the other disease conditions.  Incremental cost calculations can help 
understand the contribution of different service categories to the overall costs and 
therefore, facilitate decisions pertaining to efficient resource allocation.  
The costs assessment needs to focus on important demographic factors such as 
gender, race, age, and geographic region to better understand the disparity in terms of 
prevalence and national estimates among individuals with MSD’s.  Specifically, studies 
have shown that women and elderly are majorly affected by MSD’s.  Thus, assessing the 
treatment cost of MSD's based on demographic profiles would further help in 
determining the predictors of resource utilization and identifying US regions where there 
is a high prevalence and resource utilization.  The study estimates can serve as a guide for 
policy makers in the formulation of health care policies on screening, treatment 
guidelines, and identification of high-risk population for MSD's.  
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Conceptual Framework 
The objective of this study is to develop a national assessment of the incremental 
resource utilization in individuals with MSD’s compared to those without MSD’s, using a 
retrospective analysis of 2007 Medical Expenditure Panel Survey (MEPS) data.  
Incremental cost analysis is a decision-making technique used to determine the true cost 
difference between alternatives.  In addition to calculating the incremental costs, the 
study has two more objectives.  First, to focus on the different  health care service 
categories that contribute to the overall health care expenditures in individuals with 
MSD’s and non-MSD’s  and second, to evaluate the disparity in demographic variables 
such as age, gender, race, and geographic location on different health care service 
categories.  
The study will use 2007 MEPS data for all the analysis. MEPS is a third in the 
series of nationally representative surveys of medical care use and expenditure sponsored 
by the Agency for the Health Care Policy and Research (AHCPR).
27  
MEPS database 
provides national information on the types of health services used in the US, and how 
frequently the health services are used.   
MEPS database comprises of three components. These include: 
1) Household component (HC): Provides detailed information on the demographic 
characteristics, health status, health insurance, employment, and medical care use and 
expenses of the individuals. 
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2) Medical Provider Component (MPC): Provides additional information on specific 
International Classification of Diseases - 9 ( ICD-9) codes, Current Procedural 
Terminology (CPT) codes and Diagnosis-Related Group (DRG) codes used by the 
physicians and hospitals. 
3) Insurance Component (IC): Provides data on the number and types of private health 
insurance plans offered, benefits associated with these plans, premiums, contributions by 
employers and employees, eligibility requirements, and employer characteristics. 
The study will use the HC and MPC of the 2007 MEPS database.  The study will 
identify the individuals diagnosed with MSD's and those without MSD’s, and categorize 
them into two cohorts based on the ICD-9 codes.  Overall disease burden, incremental 
costs, health care expenditures including different service categories and demographic 
disparities in health care expenditures will be estimated in the two cohorts. 
Hypothesis 
 The overall hypothesis is that resource utilization in individuals with MSD’s will 
be higher than the non-MSD cohort. 
 
Study Objectives  
The specific study objectives include: 
Objective 1: To identify the characteristics of the total population surveyed in 2007 
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MEPS data.  
Objective 2: To identify the demographic characteristics of individuals diagnosed with 
MSD's and non-MSD in 2007 MEPS data.   
Objective 3: To estimate the mean expenditures for total health care expenditures, total 
office-based expenditures, total outpatient expenditures, total inpatient expenditures, total 
emergency room expenditures, total office-based chiropractor expenditures, and total 
prescription expenditures in individuals with MSD's and non-MSD.  
Objective 4: To identify the predictors for total health expenditures, total office-based 
expenditures, total outpatient expenditures, total inpatient expenditures, total emergency 
room expenditures, total office-based chiropractor expenditures, and total prescription 
expenditures in individuals with MSD's and non-MSD.  
Objective 5: To calculate a national estimate for the total incremental health care 
expenditures of MSD's compared to non-MSD.  
 
Significance of the Study 
The overall goal of the study is to provide prevalence and cost estimates for 
MSD's using 2007 MEPS data.  The study aims at updating old cost estimates from the 
1990s since there has been a significant change in the management of MSD's.  This study 
can be instrumental in public health policy debates as it highlights the magnitude of the 
impact of MSD's on our society.  The calculation of the cost estimates for different 
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service categories are useful in understanding the value of new technologies that are 
introduced in the market.  Once the true cost impact of the disease is known, policy 
makers can then estimate the resources that could potentially be saved or gained if the 
disease is managed at an early stage.  It would also be useful to understand the possible 
cost offsets that can accrue due to the implementation of preventive programs such as 
screenings or testing.  Based on past research, preventive programs have been shown to 
be cost effective and result in efficient use of existing health care technology.  Thus, the 
overall costs assessment can help policy makers decide the right course of action in terms 
of resource allocations and prevention policies.   
Understanding the socio-demographic characteristics of individuals with MSD's 
will aid in indentifying the population at-risk by studying the predictors and by further 
studying the sub-categories which are significant for the specific health care service 
categories.  Based on the study results, emphasis can be placed on interventional 
strategies that can target these populations with a goal of reducing the disease prevalence.  
These interventions are also helpful in improving the QoL of the individuals and the 
significant resource utilization associated with MSD's.  Evidence from similar 
intervention strategies for diabetes and hypertension have shown that these strategies are 
very effective in lowering the disease incidence and reducing cost of disease 
management.
28
  This study includes a number of MSD’s such as invertible disc disorder, 
curvature of spine that are less prevalent in the population but incur significant resource 
utilizations.  In the past, studies have mainly focused on major MSD conditions such as 
RA, OA, AS, and gout.  
 14 
 
 
The study results can be used by different stake holders in developing new and 
improved disease management strategies.  From a clinician’s perspective, this study will 
provide them with information about the target population and the need for adhering to 
appropriate treatment guidelines.  This study will help managed care organizations to 
better understand the cost burden of MSD's and assist them in structuring effective 
guidelines to provide low cost and better care to individuals with MSD’s.  The study will 
further provide significant information to the policy makers for setting priorities in 
resource allocation, taking into account the huge economic impact of these conditions.  
 The next chapter will discuss the prevalence and costs studies that have been 
conducted in MSD’s. 
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CHAPTER TWO 
LITERATURE REVIEW 
This chapter provides an in-depth review of the literature for the following: (i) 
MSD's-related prevalence, (ii) Burden of MSD's on the US health care system. 
 
Search Strategy 
Following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, a systematic literature search was conducted among 
peer-reviewed journals from January 1990 to January 2012 in electronic databases such 
as Pubmed (Figure 1).
29 
 The search was limited to studies in English language.  
The search strategy included the following search terms or their combinations: 
musculoskeletal disorders, rheumatic condition, rheumatoid arthritis, osteoarthritis, joint 
pain, cost, disease burden, prevalence, epidemiology, predictors, biologics, service 
categories, inpatient, outpatient, prescription drugs, and emergency room. 
 
Inclusion/Exclusion Criteria 
Articles were included in the final review if they estimated the prevalence of 
MSD’s or if they assessed the cost impact of MSD's.  Randomized clinical trials, drug-
specific cost studies, pharmacoeconomic studies for MSD's treatments, costs studies 
conducted outside of the US, and review articles were excluded from the review.  
 16 
 
 
Figure 1.PRISMA diagram elaborates the step wise selection of studies for the literature 
search. 
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The 10 articles included in the review were categorized as follows: 
 Prevalence of MSD's. 
 Burden of MSD's on the US health care system. 
 
Prevalence of MSD's 
There are only four studies that have estimated the prevalence of MSD’s in the 
US population.  The Bone and Joint Organization used the 2008 National Health 
Interview Survey (NHIS) to estimate the prevalence of MSD's and reported 
approximately, 110.34 million adults with a musculoskeletal condition.
6
  Jacobs and 
colleagues (2008) reported a total of 107.7 million adults suffering from musculoskeletal 
conditions with one in two adults suffering from MSD's in 2005.
30 
 Older estimates 
indicate that the prevalence of MSD’s in the US has increased at an alarming rate.  Yelin 
and colleagues (2001) reported a prevalence rate of 53.93 million adults, which was 
approximately 20.1% of the US population in 1996.
24
  Another study by Lawrence and 
colleagues (1998) used the 1990 National Health and Nutrition Examination Survey 
(NHANES) data to estimate the prevalence of MSD’s and then extrapolated the results to 
the year 2020.  Approximately, 37.9 million (15%) individuals in 1990 had some form of 
arthritis or rheumatic condition and MSD cases were predicted to increase to 59.4 million 
(18.2%) by 2020.
31
 
Yelin and colleagues (2007) expanded the definition of MSD’s to include other 
rheumatic conditions such as rheumatic fever, other peripheral vascular disease, and 
polyarteritis nodosa and allied conditions and labeled the group as arthritis and other 
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rheumatic conditions (AORC).  The authors estimated the prevalence of AORC between 
1997 and 2003 using MEPS database.  The prevalence of AORC in 1997 was 36.799 
million adults (18.7% of the US population), and increased to 46.114 million in 2003 
(21.5% of the US population).
32
  Some prevalence data have also been reported for 
specific MSD conditions such as RA, OA, AS, and gout.  Simon and colleagues (2012) 
reported the prevalence rates of RA over three consecutive years: 0.40% in 2004, 0.44% 
in 2005, and 0.43% in 2006.  Helmick and colleagues (2008) used 2005 National Health 
Interview Survey (NHIS) data to estimate the prevalence of OA, AS, and gout.  Nearly 27 
million adults had clinically proven osteoarthritis (up from 21 million in 1995).  The 
prevalence rate of AS was 30 - 900 per 100,000 and gout was self-reported by 3 million 
adults (up from 2.1 million in 1995).
33
  
Prevalence estimates from the literature suggests that the rate has nearly doubled 
in the last two decades.  The prevalence of MSD's in the US shows a rising trajectory 
especially due to the dramatic growth in numbers and proportions of the elderly coupled 
with increased life expectancies. 
 
Burden of MSD's on the US Health Care System 
 Three studies have reported economic burden of MSD's on the US health care 
system.  Jacobs (2008) estimated the total cost for MSD’s treatments at $849 billion with 
$510 billion in direct costs and $339 billion in indirect costs.  Just like the prevalence 
data, older estimates are considerably lower than the newer estimates.
30
  Yelin and 
colleagues (2001) utilized the 1996 MEPS data to estimate the national expense and 
individual’s annual average medical care expense for MSD’s.  The national expense for 
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MSD’s was estimated at $193 billion with an individual’s annual average expense at 
$3,578.
24  
In another study, Yelin and colleagues (2004) expanded the definition of 
MSD’s by including rheumatic conditions and used this group to estimate the earning 
losses of individuals with AORC.  Estimates from the 1997 MEPS data indicated a total 
of 38.4 million individuals with AORC, with an individual’s mean total medical 
expenditure at $4,865 and a national annual burden of $186.9 billion.
32
 
 Yelin and colleagues conducted two studies that estimated the predictors of 
resource utilization.  The first study utilized the 1996 MEPS data to study the predictors 
of MSD’s while the second study utilized the 2003 MEPS data to study the predictors 
AORC.  For both MSD’s and AORC, inpatient cost was the biggest contributor to the 
total resource utilization.  In MSD's, inpatient cost was 37% of the total cost compared to 
32% for AORC.  After inpatient costs, outpatient costs were the next category that 
contributed most to the resource utilization.  For MSD's, the outpatient costs contributed 
23% to the total cost while for AORC, it was 32%.  Since the additional conditions 
included under AORC compared to MSD’s require more outpatient treatment, there is a 
trend for more expenditure on an outpatient basis for AORC compared to MSD’s.  
Similarly, MSD’s require more hospitalizations and therefore, the trend for MSD’s was 
higher expenditures in inpatient setting compared to AORC.  Prescription drug costs were 
also a major contributor to the overall cost for MSD’s (16%) and AORC (23%).24, 32 
Predictors of resource utilization for specific musculoskeletal conditions have also 
been reported in the literature.  Lurie and colleagues (2008) estimated the out-of-pocket 
costs in individuals with RA from 1998 to 2004 using MEPS data.  The total out-of-
pocket expenditures among individuals with RA increased by 52.5%, primarily due to a 
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72% increase in the median out-of-pocket expenditures for RA prescription drugs from 
1998 to 2004.
34
  Gabriel and colleagues (1997) estimated the direct medical costs 
associated with OA and RA and compared the costs to a control group which included 
individuals without arthritis.  The use of prescription medications was higher for RA 
(96.3%) and OA (96%) compared to the control group (83%).
35
 
Studies have calculated the incremental costs of MSD’s compared non-MSD. 
Individuals with MSD’s had 50% higher care expenditures ($3,578) compared to the non-
MSD's cohort ($2,313) with a national incremental cost of $193 billion.  Another study 
calculated the mean incremental medical care expenditures attributable to AORC 
reported an incremental cost of $1,752, with a national burden of $80.8 billion.
24, 32 
  
This review highlights the paucity of recent estimates of MSD’s prevalence rates, 
total economic burden, and the predictors of resource utilization.  The goal of the current 
study is to provide newer estimates based on the 2007 MEPS data.
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CHAPTER THREE 
METHODOLOGY 
 
This chapter describes data source, data extraction, independent and dependent 
variables, and the statistical analyses used in the study. 
 
Data Source  
The study utilized 2007 Medical Expenditure Panel Survey (MEPS) data for all 
the analyses.  The MEPS data is sponsored by the Agency for Health Care Policy and 
Research (AHCPR) and is administered annually since 1996.  The MEPS data measures 
the frequency of the health care services utilized by US civilian non-institutionalized 
population and provides national estimates of the medical use and total expenditures of 
health care resources.  In addition to the treatment cost, the database also provides 
demographics (e.g., age, gender, and race), and insurance information (e.g., public, 
private, and uninsured) of the participants.  
The MEPS data is collected through a series of five rounds of interviews that span 
a period of 2½ years.  The interviews are conducted on a nationally representative sample 
of households using an overlapping panel design.  Since the current study is conducted 
using a cross-sectional 2007 MEPS data, analytical adjustments were made using sample 
weights to accommodate the panel design.  In complex survey designs, such as that used 
in MEPS, sample data must be multiplied by the appropriate sample weights to obtain 
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unbiased estimates for the US civilian non-institutionalized population.  Sample weights 
provided within the MEPS data were used to estimate the national and regional 
expenditures of different health care service categories.  The sample weights also account 
for equal representation of certain sections of the society which have been under 
represented in the surveyed population.  These weights are also needed to correct for 
imperfections in the sample that might lead to bias and other departures between the 
sample and the reference population.  Such imperfections include the selection of units 
with unequal probabilities, non-coverage of the population, and non-response. 
The MEPS data includes the following three components: 
1) Household Component: The Household Component (HC) is a national representative 
survey of the non-institutionalized civilian population.  The structure and design of HC is 
very descriptive and provides detailed information on the population’s demographic 
characteristics, health status, employment status, and their access to health care services.  
This component helps in understanding the complex research objectives such as the use 
of health services and expenditures, changes in provision of health care in relation to 
social and demographic factors and needs of a specific population group such as the 
elderly and children.  
2) Medical Provider Component: The Medical Provider Component (MPC) is a survey of 
the medical providers, facilities, and pharmacies that provide health care services to 
individuals and families included in the survey.  This component provides detailed 
information on the expenditure and payment sources of the respondents.  
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3) Insurance Component: The Insurance Component (IC) is designed to estimate the 
national and state-level cost of employer-sponsored coverage's.  These estimates provide 
information on the amount spent, type of insurance, and cost of the job-related health 
insurance.  
MEPS data provides information that can be useful in conducting a variety of 
research projects. Some examples include: 
1) Research on health care expenditure and their sources of payments: MEPS data 
provides in-depth information on individual’s total and out-of-pocket health care 
expenditures.  The amount of health care services such as outpatient facility, inpatient, 
prescription drug, emergency room, and their sources of payment like Medicare, 
Medicaid, or private insurance can also be estimated.  
2) Research on vulnerable population groups: The disparity in the utilization of health 
care resources and access to care among different population groups have been of 
immense concern to policymakers.  MEPS data can provide valuable information to 
policy makers regarding the size and composition of a particular subset of population that 
are disadvantaged in terms of access and use of the various health care resources.   
3) Research on private and public health insurance: MEPS data provides information on 
the health insurance status of the individuals and their family members.  Additional 
insurance information such as premiums, employer and employee contributions, types of 
plans, and details on the scope and copayment provisions is available.  The data is useful 
in estimating the health insurance in general, the interplay of specific insurance plans, 
and the use of health care resources.  
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The 2007 MEPS data contains variables and frequency distributions of 30,964 
individuals who participated in the HC.  
 
Study Population 
 The study population was divided into two cohorts based on the presence or 
absence of MSD's. Individuals with a primary diagnosis of conditions included under 
MSD’s were selected.  Table 1 lists all the disease conditions that are included under 
MSD’s.  The individuals categorized in the MSD cohort had ICD-9-CM codes of 278.00 
and 710.00-738.00.  Individuals without the MSD’s codes were categorized into the non-
MSD cohort. 
 
Data Extraction 
 
The 2007 consolidated full year file and medical conditions file were downloaded 
from the MEPS website (http://meps.ahrq.gov).  The files were unzipped and 
decompressed to extract the data in ASCII format.  The ASCII files were then converted 
to Predictive Analytical Software (PASW) version 18.0 with the help of SPSS load 
programs which were also downloaded from the MEPS website.  The consolidated full 
year file and medical conditions file were then merged using the ICD-9-CM codes for 
MSD's (274.00 and 710.00-738.00).  
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Table 1: Disease conditions categorized under MSD's 
  
ICD-9-CM DISEASE CONDITION 
274.00 Gout 
710.00 Systemic lupus erythematosus 
711.00 Arthropathy associated with infections 
712.00 Crystal arthropathies 
713.00 Arthropathy, endocrine disorders 
714.00 
715.00 
Rheumatoid arthritis 
Osteoarthrosis 
716.00 Other & unspecified arthropathies 
717.00 Internal derangement of knee 
718.00 Other derangement of joint 
719.00 Other & unspecified disorders of joint 
720.00 Ankylosing spondylitis 
721.00 Spondylosis & allied disorders 
722.00 Intervertebral disc disorders 
723.00 Other disorders of cervical region 
724.00 Other & unspecified disorders of back 
725.00 Polymyalgia rheumatica 
726.00 Peripheral enthesopathies & allied syndromes 
727.00 Other disorders of synovium, tendon, & bursa 
728.00 Disorders of muscle, ligament, & fascia 
729.00 
730.00 
Other disorders of soft tissues 
Osteomyelitis, periostitis, & other infections  
731.00 Osteitis deformans & osteopathies  
732.00 Osteochondropathies 
733.00 Other disorders of bone & cartilage 
734.00 Flat foot 
735.00 Acquired deformities of toe 
736.00 Other acquired deformities of limbs 
737.00 Curvature of spine 
738.00 Other acquired musculoskeletal deformity 
________________________________________________________________________
ICD-9 CM: The International Classification of Diseases Ninth Revision Clinical Modification 
Based on the recommendation of the National Arthritis Workshop (1996) 
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Independent Variables 
Presence of MSD's 
The main variable was the presence of MSD's. In the MEPS data, the medical condition 
of the respondents was provided as ICD9CODX which was recoded into a new variable 
“MSD” and categorized as “Yes” and “No". 
Census Region 
This variable provides geographic information of the survey respondents. In the MEPS 
dataset, geographic region information was provided as REGION07.  It was recoded into 
a new variable "Census Region".  The patient’s geographic region was categorized as: 
Northeast, Midwest, South, and West.   
Age  
This variable provides information on the age of a respondent and was reported as a 
continuous variable.  In the MEPS dataset, age information was provided as AGE07X.  
This variable was recoded as "AGE IN YEARS", by dividing the sample into four 
categories 0-18 years, 19-40 years, 41-64 years, and 65 years and above.  
Race 
This variable provides information on the race of a respondent.  In the MEPS dataset, 
race information was provided as RACEX.  This variable was recoded as "RACE".  In 
MEPS, the variable race was categorized into White, Black, Asian, Pacific Islander, 
Native American, and Mixed race.   
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Gender 
This variable provides gender information of the survey respondents. In the MEPS 
dataset, gender information was provided as "SEX".  The gender variable was 
categorized as male and female. 
Education 
This variable represented the education in years for the survey respondents. In MEPS, 
education years information was provided as EDUCYR.  This variable was recoded as 
"EDUCATION YEARS".  Education in years was originally recorded as a continuous 
variable and was recoded as categorical variables with three categories: less than 12 years 
of education, individuals with 12 years of education, and individuals with more than 12 
years of education. 
Marital Status 
This variable provides information about the marital status of the survey respondents.  In 
MEPS, marital status information was provided as MARRY07X.  This variable was 
recoded as "MARITAL STATUS".  This variable represents the marital status of an 
individual and was categorized as Married, Separated, Never Married, and under the age 
of 16 years. 
 
Outcome Variables 
Total Health Care Expenditures  
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This variable provides the total health care expenses and is useful in estimating the 
overall burden of MSD’s on the health care system.  
Total Office-based Chiropractor's Expenditures 
This variable provides the office-based chiropractor's expenses.  This expense is a part of 
the office-based expense which the individuals with MSD's incur. 
Total Inpatient Facility Expenditures 
This variable provides the inpatient facility expenses including procedures and drugs for 
the MSD’s and the non-MSD population. 
Total Outpatient Facility Expenditures 
This variable provides the total outpatient facility expenses including physician and non-
physician care visit charges for MSD’s and non-MSD population. 
Total Emergency Room Expenditures 
This variable provides the total emergency room expenses for MSD’s and non-MSD 
population. 
Total Prescription Drug Expenditures 
This variable provides the total cost of prescription drugs for MSD's and non-MSD 
population. 
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Data Analysis 
Data was analyzed using Predictive Analytical Software (PASW) version 18.0.  
As discussed earlier, national estimates from MEPS data was calculated by applying 
sample weights.  
For all the regression models, a p-value of 0.05 was selected a priori as the 
significance level.  For the analysis, a simple linear regression model was used: 
 Y = C + B1X1 + B2X2 …..+ E  
Y = Dependent variable, C= Intercept, B1, B2 = Beta coefficients, X1, X2 = 
Independent variables, E = Error component  
The dependent variable in the regression model was the total expenditures for 
different service categories while the independent variable was the presence of MSD's.  
Age, gender, race, marital status, census region and education years were included as 
independent variables in the analysis.  The model was based on the study by Balu and 
colleagues that estimated the incremental expenditure of hypertension.
36
  
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census region + B7Education years + E 
 
Assumptions for Regression Model 
The following assumptions were tested before the regression analyses were 
conducted and no serious violations of the assumptions were observed.  Here the 
independent variables (IVs) refer to age, gender, race, marital status, census region, 
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education years and the dependent variables (DVs) refer to the total health care 
expenditures, total office-based chiropractor expenditures, total outpatient expenditures, 
total inpatient expenditures, total emergency room expenditures and total prescription 
expenditures. 
Linearity of the relationship between the IV and the DV  
 If the relationship between IV and DV is not linear; the regression analysis results 
most likely under-estimate the true relationship.  We conducted scatter plots of both IV 
and DV and found the relationship to be linear.  In order to quantify the strength of the 
linear relationship, a numerical measure of association between the two variables was 
estimated using the correlation coefficient.  A value between -1 and 1 indicated the 
strength of the association of the observed data for the two variables.  Our results 
indicated that there was a strong linear relationship between the IVs and DVs since the 
coefficient correlation values were greater than 0.4. 
Independence of errors to check for no serial correlation  
 Independence of the variables in a reported data is based on the assumption that 
all the variables recorded at the time of collection are independent.  In order to determine 
the independence of variables, two tests were conducted.  Tolerance is the proportion of a 
variable's variance that is not accounted for by the other IVs in the equation.  A tolerance 
value close to 1 indicates very little multicollinearity, whereas a value close to 0 suggests 
that multicollinearity may be a threat.  For this study, all the tolerance estimates were 
around 1 indicating very little or no multicollinearity.  The second test to check for 
independence was the Variance Inflation Factor (VIF) which is the reciprocal of tolerance 
and quantifies the severity of multicollinearity in a regression analysis.  The acceptable 
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range of VIF is a score less than 10. For this study, the VIF scores for all the IVs were 
less than 10, further indicating very little or no multicollinearity. 
Homoscedasticity (assumption of constant variance) 
  The assumption of homoscedasticity is that the residuals are approximately equal 
for all predicted DVs scores.  Homoscedasticity was tested by conducting scatter plots 
between each IV and DV.  In the residual plots, the clusters of points were approximately 
the same width indicating that DVs exhibited similar amounts of variance across the 
range of values for the IVs. 
Normality of the error distribution 
 The sample size in the 2007 MEPS data was 94,246.  According to Central Limit 
Theorem, a sample distribution is approximately normal if the sample size is greater than 
30.  So the data was considered approximately normal.  We still tested this assumption 
using two tests.  Kurtosis is a measure of the shape of the probability distribution of a 
real-valued random variable.  For a distribution to be normal, kurtosis scores should be 
within the range of -1 to +1. Study results were in the acceptable range of -1 to +1.  
Skewness was also conducted to check for normality.  Skewness is a measure of the 
asymmetry of the probability distribution of a real-valued random variable.  The 
acceptable range for skewness test is -1 to +1 for a normal distribution.  The study results 
were also in the acceptable range.  Both these tests confirmed the normality of the data. 
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Regression Analysis 
 For the regression analysis “Enter” Method was used. "Enter" method enters all 
variables into the regression model at the same time.  This is the default method to 
conduct a regression analysis in SPSS. Other hierarchical methods that are used in 
regression models include “Backward”, “Forward”, and “Stepwise”.  The hierarchical 
methods are used when specified order should reflect some theoretical consideration or 
previous findings.  “Enter” method was selected for the analysis because there was no 
reason to believe that one variable is likely to be more important than another.  
The following analyses were conducted based on the specific study objectives. 
Objective 1: To identify the characteristics of the total population surveyed in 2007 
MEPS data.  
The frequencies for all the individuals in the database were assessed.  The mean 
age was reported and the frequencies for age, gender, race, marital status, education 
years, and census region were analyzed.  Sample survey weights were used to estimate 
the weighted and non-weighted prevalence of the MSD's. 
Objective 2: To identify the demographic characteristics of individuals diagnosed with 
MSD's and non-MSD in 2007 MEPS data.   
The frequencies for age, gender, race, educational years, marital status, and 
census region for the individuals with MSD’s was reported  
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In objectives 3, 4, and 5, the following regression model will be used for the estimation 
of costs.  
Y= Intercept + B1X1 + B2 X2 + B3 X3 + B4 X4 + B5 X5 + B6 X6 + B7 X7 + E 
where B1-B7 = Beta Coefficients; E = Error term; Dependent Variable = Expenditures; 
Independent Variables = Presence of MSD, Age, Gender, Race, Marital Status, Census 
Region, Education years. 
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census Region + B7Education years + E 
In the regression model, intercept is where the regression line strikes the Y axis 
when the independent variable has a value of 0. B1 is the slope of the IV (e.g., presence of 
MSD’s).  Similarly B2, B3, B4, B5, B6, B7 are the slopes of other independent variables age, 
gender, race, marital status, census region, and education years, respectively.  E is the 
error component in the estimation of the total cost.  The predicted value is calculated as 
follows:  
Predicted variable (dependent variable) = slope * independent variable + intercept 
Objective 3: To estimate the mean expenditures for total health care expenditures, total 
office-based chiropractor's expenditures, total outpatient expenditures, total inpatient 
expenditures, total emergency room expenditures and total prescription expenditures in 
individuals with MSD's and non-MSD.  
A separate dataset was created to calculate the mean expenditures in each service 
category for individuals with a MSD diagnosis.  Descriptive analysis was conducted and 
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a linear regression model was utilized to estimate the mean total health care expenditures, 
mean total office-based chiropractor expenditures, mean total outpatient expenditures, 
mean total inpatient expenditures, mean total emergency room expenditures and mean 
total prescription expenditures.  Certain independent variables were recoded as dummy 
variables to examine any possible effect of the categorical variable on the DV.  The 
variables that were recoded were age, race, marital status, and education years. 
The regression model used in the analysis was:  
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census Region + B7Education years + E 
Objective 4: To identify the predictors for total health expenditures, total office-based 
chiropractor expenditures, total outpatient expenditures, total inpatient expenditures, 
total emergency room expenditures and total prescription expenditures in individuals 
with MSD's.  
To identify the predictors of expenditures in each service category, a separate 
dataset was created that contained individuals with a MSD diagnosis alone.  A linear 
regression model was utilized to estimate the mean total health care expenditures, mean 
total office-based chiropractor expenditures, mean total outpatient expenditures, mean 
total inpatient expenditures, mean total emergency room expenditures and mean total 
prescription drug expenditures.  The model used was  
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census Region + B7Education years + E 
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Objective 5: To calculate a national estimate for the total incremental health care 
expenditures of MSD's compared to non-MSD.  
To calculate a national estimate for the incremental health care expenditures for 
treating MSD's, mean cost of individuals with non-MSD diagnosis was conducted.  A 
separate dataset with only individuals with non-MSD conditions were included.  A linear 
regression model was run, using the “Enter” method.  Cost of treatment under separate 
service category for the mean total health care expenditures, mean total office-based 
chiropractor expenditures, mean total outpatient expenditures, mean total inpatient 
expenditures, mean total emergency room expenditures and mean total prescription 
expenditures were calculated.  The incremental difference between MSD's and non-MSD 
was calculated.  The mean incremental difference was then multiplied by the prevalence 
of MSD's cases for the year 2007. 
National estimate for the total incremental health care expenditures = National 
Prevalence × estimated incremental expenditures 
 
Adjustment of Total and Incremental Costs to 2011 Values: 
The costs from the 2007 MEPS data was inflated to year 2011 value by using the 
standardized inflation rates published by the Bureau of Labor Statistics (BLS).
37
  This 
adjustment presents the economic burden of MSD’s on the society in today’s value.  
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CHAPTER FOUR 
RESULTS 
 
In this chapter, results for each of the study objectives are presented. 
The full year consolidated data file and the medical component file of the 2007 
MEPS data was utilized.  From this dataset, patients were categorized as MSD’s and non-
MSD.  Based on the National Arthritis Workshop recommendations, patients with ICD-9-
CM codes of 274.00 and 710.00 to 738.00 as their primary diagnosis were categorized as 
having MSD’s and the rest were categorized as non-MSD.38  The 2007 MEPS database 
surveyed a total of 94,246 individuals.  After the sample weights were applied, the 
national data represented 301,309,149 individuals. 
 
Objective 1: To identify the characteristics of the total population surveyed in 2007 
MEPS data. 
 A descriptive analysis was conducted to determine the frequencies (weighted and 
unweighted) of age, gender, race, education years, geographic region, and census region 
of the population surveyed in 2007 MEPS data (Refer Table 2).  In the survey population 
(n=94,246), a majority of the respondents were under 18 years of age (30.8%) followed 
by 41 to 65 years (29.9%).  The mean age of the respondents was 34.53±22.73 years 
(Mean±SD).  There were 52.1% females and the survey population was predominantly 
white (74.5%), married (38.9%), with >12 years of education (44.9%), and from the 
Southern region of the US (38.0%).  
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Table 2: Characteristics of the total population surveyed in 2007 MEPS data.  
 
Variable   level  Unweighted data  Weighted data 
      N (%)   N (%) 
Age (years) (Mean±SD)     34.53±22.73              36.51±22.60  
Age (years)  0 - 18   9,460 (30.8)  92,803,217 (31.0) 
   19 - 40   8,803 (28.6)  86,174,416 (28.3) 
   41-65   9,206 (29.9)  90,091,435 (30.2) 
   > 66   3,278 (10.7)  32,240,078 (10.5) 
Gender  Male   14, 817 (47.9)  144,327,082 (47.9) 
   Female  16, 417 (52.1)  156,982,066 (52.1) 
Race/ Ethnicity White    23,705 (74.5)  224,475,316 (74.6) 
   Black   5,404 (17.5)  52,729,101 (17.5) 
   American Islander &       
   Native Hawaiian 387 (1.2)  3,615,709 (1.2)    
   Asian   1,442 (4.7)  14,161,530 (4.6) 
   Mixed race  656 (2.1)  6,327,492 (2.1) 
Census Region Northeast   4,517 (14.7)  44,292,444 (14.7) 
   Midwest  6,224 (20.2)  60,864,448 (21.1) 
   South   11,699 (38.0)  114,497,476 (37.0)  
   West   8,307 (27.0)  81,353,470 (27.2) 
Marital Status   Married   12, 044 (38.9)  117,209,259 (38.0) 
   Separated  4,417 (14.3)  43,087,208 (15.0) 
   Never Married  6,600 (21.3)  64,178,848 (21.5) 
   Under 16 years of  
   age    7,893 (25.5)  76,833,833 (25.5) 
Education Years <12 years   4,656 (22.4)  67,493,249 (22.5) 
   12 years   6, 812 (32.7)  98,528,091 (32.5) 
   > 12 years   9,336 (44.9)           135,287,807 (45.0) 
N = Number of individuals 
SD = Standard deviation 
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 Objective 2: To identify the demographic characteristics of individuals diagnosed with 
MSD's and non-MSD in the 2007 MEPS data.   
 Among the surveyed individuals (n= 94, 246), 10, 696 (11.3%) were categorized 
as MSD's and the rest were categorized as non-MSD (n= 83,550; 88.7%).  The weighted 
national population of MSD’s and non-MSD were 33,075,541 (11.3%) and 268,233,608 
(88.7%), respectively.  
 The mean ages for individuals with MSD’s and non-MSD were 34.63±22.99 
years and 34.51±22.70 years, respectively.  In the MSD’s and non-MSD cohort, a 
majority of the individuals were under 18 years of age (31.1%, 30.7%) followed by 41 to 
65 years (30.0%, 29.9%).  Females (52.1%, 52.2%), whites (75.1%, 74.4%), individuals 
with >12 years of education (43.4%, 45.1%), and Southern region of the US (38.6%, 
38.0%) were predominant among both the MSD's and non-MSD cohort.  
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Table 3: Demographic characteristics of MSD’s and non-MSD in the 2007 MEPS data. 
  MSD Non-MSD          P-value 
Variable Level N (%) N (%) 
Age (years) (Mean±SD) 
 
Age (years) 
 
 
0-18 
34.63±22.99 
 
1,071(31.1) 
34.51±22.70       0.782* 
 
8,389 (30.7)      0.778** 
 19-40 960 (27.9) 8,175 (28.7) 
 41-65 1,031(30.0) 8,175 (29.9) 
 >66 379 (11.0) 2,899 (10.6) 
    
Gender Male 1,662 (47.9) 13,155 (47.8)     0.929** 
 Female 1,806 (52.1) 14,341 (52.2) 
    
Race/Ethnicity White 2,605 (75.1) 20,470 (74.4)     0.920** 
 Black 596 (17.2) 4,808 (17.5) 
 Native American 
& Hawaiian 
Islander                      
 
 
41 (1.1) 
 
 
346 (1.2) 
 Asian 157 (4.5) 985 (3.6) 
 Multiple Races 69 (1.9) 587 (2.1) 
    
Census Region  Northeast 483 (14.0) 4,034 (14.8)       0.681** 
 Midwest 703 (20.4) 5,521 (20.2) 
 South 1,328 (38.6) 10,371 (38.0) 
 West  927 (26.9) 7,380 (27.0) 
    
Marital Status Married 1,324 (38.2) 10,720 (39.0)     0.632** 
 Separated 484 (14.0) 3,933 (14.3) 
 Never Married 757 (21.8) 5,843 (21.3) 
 Under 16 years of 
age  
903 (26.0) 6,990 (25.4) 
    
Education Years < 12 years 538 (23.1) 4,118 (22.3)       0.323** 
 12 years 779 (33.5) 6,033 (32.6) 
 >12 years 1,011(43.4) 8,325 (45.1) 
    
N= Number of individuals, SD = Standard deviation, *Independent t-test  , ** Chi-square test, Significance at p<0.05 
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Objective 3: To estimate the mean expenditures for total health care expenditures, total 
office-based expenditures, total outpatient expenditures, total inpatient expenditures, 
total emergency room expenditures, total office-based chiropractor expenditures, and 
total prescription expenditures in individuals with MSD's and non-MSD. 
In order to estimate the cost of treatment for different service categories, two 
separate datasets were created.  The first dataset contained individuals with a diagnosis of 
MSD's.  All the other individuals without the MSD diagnosis were included into the non-
MSD dataset.  A multiple linear regression was conducted to estimate the mean health 
care expenditures for individuals with MSD's and non-MSD under different service 
categories like total health care expenditures, office-based expenditures, outpatient 
expenditures, inpatient expenditures, emergency room expenditures, office-based 
chiropractor expenditures, and prescription expenditures.  The regression model used for 
the two cohorts was: 
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census Region + B7Education years + E  
where B1-B7 = Beta Coefficients 
E = Error term 
Dependent Variable = Expenditure 
Independent Variables = Presence of MSD, Age, Gender, Race, Marital Status, Census 
Region, Education years 
The mean total health care expenditures for the MSD's cohort were $91,121.41 
compared to $90,234.91 for the non-MSD cohort (p< 0.05).  The non-zero confidence 
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interval suggested that there was a significant difference between the cost estimates of the 
two cohorts.  In both MSD’s and non-MSD, inpatient facility expenditures were the 
highest ($33,461.85; $30,798.62) followed by prescription drug expenditures 
($26,384.35; $25,651.44), and office-based expenditures ($16,338.80; $16,834.81).  The 
emergency room expenditures and the office-based chiropractor expenditures made 
smaller contributions to the overall health care expenditures in both the cohorts. 
 Similar to the total health care expenditures, expenditures for each service 
category was estimated.  Table 4 represents the parameter estimates for each IV in both 
the cohorts.  The mean expenditures for each service category were calculated using the 
parameter estimates for each respondent as follows: 
Beta coefficient * IV + Intercept = Mean cost under each service category………….. (1) 
For example, the total health care expenditures for a respondent were calculated as:  
Total health care expenditureindividual = 683.144-595.26*(sex)-447.1*(census region) 
+128.31*(marital status)-409.11*(race) +2795.348*(age)-652.576*(education years) 
Substituting the values of IVs for each respondent in the above equation, the total health 
care expenditures were calculated as: 
 Total health care expendituresindividual = 683.144-595.26*(2)-447.1*(3) +128.31*(6)-
409.11*(1) +2795.348*(9)-652.576*(2) = $198,532.31 
The sum of the total health care expenditures for all the respondents with MSD’s gave the 
total health care expenditures of the MSD’s cohort.  Similarly, the total health care 
expenditures for the non-MSD cohort were calculated.  Table 5 presents the mean 
expenditures for the different service categories in the MSD's and non-MSD cohort. 
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Table 4. Parameter estimates for different service categories in MSD's and non-MSD cohorts 
Independent 
variables 
Total health care expenditures Total inpatient facility expenditures Total prescription drug expenditures 
 MSD's Non-MSD MSD's Non-MSD MSD's Non-MSD 
 B C.I B C.I. B C.I. B C.I. B C.I. B C.I. 
Intercept 683.144 -4906.05       
-        
6272.33* 
-3503.218 -4869.27              
-                       
-2137.51* 
1568.623 -1919.39             
-             
5056.64 
-1238.852 -2210.14            
-                  
-267.56* 
-1350.303 -1967.59          
-                       
-733.07* 
-1217.826 -1509.15       
-                  
-926.51* 
Gender -595.263 
-1973.40         
-          
782.87 
779.481 446.05              
-             
1112.94* 
-592.237 -1452.28             
-                
267.81 
11.308 -225.79         
-              
248.40 
162.009 9.80                  
-              
314.01* 
184.832 113.71             
-              
255.94* 
Census 
Region 
-447.129 -1130.47       
-             
235.82 
20.798 -141.08              
-            
182.67 
-337.563 -763.76              
-                
88.64 
84.408 -30.69              
-              
199.50 
-45.780 -121.20            
-            
29.64 
-8.524 -43.04              
-                
25.99 
Marital Status 128.131 -754.08         
-        
1010.34 
229.673 17.56                    
-             
441.78* 
1.102 -549.45           
-            
551.65 
94.769 -56.04                
-             
245.45 
153.642 56.20              
-           
251.07* 
92.071 46.84           
-              
137.30* 
Education 
Status 
-409.115 -1548.98         
-              
730.75 
-480.639 -762.05          
-                      
- 199.24* 
-364.159 -1075.71           
-                
347.19 
-287.762 -487.83            
-                
87.86 
-67.068 -192.96             
-                
58.82 
-129.102 -189.10             
-                       
-69.09* 
Age 2795.348 1756.50          
-             
3834.29 
2788.223 2543.21               
-              
3042.25* 
1078.377 430.00              
-              
1726.07* 
125.053 803.75                 
-            
1164.96* 
803.876 689.13              
-               
918.62* 
799.680 745.51              
-             
853.84* 
Race/ 
Ethnicity 
-652.576 -1493.21        
-               
188.06 
-16.529 -210.59              
-                  
177.54 
-214.531 -738.96            
-                
310.26 
984.362 -12.93              
-              
263.04 
-96.367 - 189.21            
-                        
-3.52* 
-43.489 -84.87              
-                  
-2.10 
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Table 4 (continued). Parameter estimates for different service categories in MSD's and non-MSD cohorts  
MSD = Musculoskeletal disorders, Non-MSD = Non musculoskeletal disorders, B = intercept, C.I . = Confidence interval, * Significant at p< 0.05 
Independent 
variables 
Total outpatient facility 
expenditures 
Total office-based expenditures Total office-based 
chiropractors expenditures 
Total ER facility expenditures 
MSD's Non-MSD MSD's Non-MSD MSD's Non-MSD MSD's Non-MSD 
 B C.I. B C.I. B C.I. B C.I. B C.I. B C.I. B C.I. B C.I. 
Intercept -73.443 -536.35  
-    
389.44 
60.054 -162.08     
-    
282.13 
666.763 -1322.05     
-                  
2655.73 
-597.631 -1108.26   
-                
-86.99 
-37.799 -123.63          
-                    
48.03 
-71.590 -116.20        
-                   
-27.16* 
155.700 -172.98           
-                     
484.38 
73.548 0.022                
-                        
147.07* 
Gender -31.637 -147.55   
-     
82.50 
52.891 -1.32          
-     
107.10 
-81.632 -572.05       
-                  
408.79 
339.841 215.90     
-                
464.49* 
12.176 -8.93             
-                    
33.43 
7.807 -3.03            
-                  
18.65 
42.515 -38.53             
-                      
123.58 
0.456 -17.49             
-                      
18.40 
Census 
Region 
22.300 -34.26     
-      
78.86 
-41.448 -67.76       
-               
-15.13* 
-108.633 -351.66       
-                  
134.40 
-24.550 -85.08       
-                
35.89 
11.749 1.23              
-                   
22.24* 
0.399 -4.86            
-                    
5.66 
2.251 -37.91             
-                      
42.71 
3.947 -4.76             
-                     
12.66 
Marital 
Status 
-6.525 -79.59    
-      
66.54 
-28.571 -63.05       
-                
5.91             
-97.974 -411.91       
-                  
215.96 
-12.493 -92.22       
-                
66.43 
-1.109 -14.56            
-                    
12.52 
9.700 2.80             
-                  
16.52*   
-25.205 -77.08             
-                     
26/67 
-2.624 -14.04             
-                      
8.79 
Education 
Status 
-23.767 -118.17   
-     
70.64 
-15.199 -60.94       
-                 
30.54 
27.232 -378.40       
-                  
432.86 
-0.206 -105.39     
-                 
104.98 
1.006 -16.45           
-                    
18.52 
21.588 12.43           
-                   
30.74    
-44.374 -111.40           
-                      
22.60 
-11.799 -26.94             
-                     
3.34   
Age 170.328 84.28      
-   
256.36* 
159.265 117.97       
-                 
200.56* 
476.368 106.64        
-                 
846.08* 
494.470 399.51        
-                
589.42* 
7.544 -8.41              
-                    
23.69 
12.640 4.37                   
-                   
20.90* 
22.650 -38.44             
-                      
83.47 
22.783 9.11                
-                      
37.45* 
Race/ 
Ethnicity 
-54.852 -124.47   
-     
14.77 
-22.788 -54.338      
-                 
8.76 
-216.870 -516.19      
-                  
82.28 
-25.927 -98.47       
-                
46.61 
-3.369 -16.27           
-                    
9.54  
-5.983 -12.29          
-                    
0.325 
-18.687 -68.12             
-                      
30.74 
-0.979 -11.43          
-                      
9.46                 
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Table 5. Mean expenditures for different service categories in MSD's and non-MSD 
cohorts in the 2007 MEPS data. 
Mean Expenditures    MSD's    Non-MSD 
Total health care expenditures  $91,121.41   $90,234.91 
Office-based expenditures   $16,338.80   $16,834.81 
Inpatient facility expenditures  $33,461.85   $30,798.62 
Outpatient facility expenditures  $3,573.41   $5,252.28 
Emergency room expenditures  $493.50   $750.99 
Prescription drug expenditures  $26,384.35   $25,651.44 
Office-based chiropractor expenditures $209.97   $603.23  
MSD's = Musculoskeletal disorders 
Non-MSD = Non musculoskeletal disorders 
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Objective 4: To identify the predictors of total health care expenditures, total office-
based expenditures, total outpatient expenditures, total inpatient expenditures, total 
emergency room expenditures, total office-based chiropractor's expenditures, and total 
prescription expenditures in individuals with MSD's. 
Multiple regressions were conducted to identify factors that predicted the health 
care expenditures in MSD's.  A total of seven regression models were set up to estimate 
the predictors of the different service categories and the DVs were the health care 
expenditures in each service category.  The IV was the presence of MSD’s.  Since age, 
gender, race, census region, marital status, and education years are categorical variables, 
dummy variables for each of these variables were created and added to the regression 
model as IVs.  Table 6 reports the regression analysis for total health care expenditures in 
MSD's.  Age (41 to 65 years and 66 years and above), census region of the US (South) 
and marital status (under 16 years) were significant predictors of total health care 
expenditures for MSD's.  
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Table 6. Predictors of the total health care expenditures for MSD's in 2007 MEPS data. 
 Model  B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of 
condition 
 MSD 5782.46 1423.58 2991.26 8573.66 .000* 
  No MSD†      
        
Sex  Male -476.99 508.96 -1474.86 520.96 .349 
  Female†      
        
Age in years  0 to 18†       
  19 to 40 -2428.80 1350.17 -5076.06 218.47 .072 
  41 to 65 645.71 1436.04 -2169.91 3461.32 .000* 
  66 and above 4323.47 1534.69 1314.42 7332.56 .005* 
        
Race  White†      
  Black -614.08 785.30 -2153.80 925.61 .434 
  American Islanders 
& Native American 
-788.85 2527.80 -5745.15 4167.45 .755 
  Asian -2179.24 1826.36 -4701.38 342.90 .090 
  Multiple race -186.23 1854.98 -3823.68 3450.79 .920 
        
Education Years  <12 years†      
  12 years -342.84 841.33 -1992.43 1306.74 .684 
  >12 years 564.032 798.84 -1002.25 2130.31 .480 
Census Region  Northeast†    
  Midwest 380.38 806.78 -1201.48       1962.23         .637 
  South -1656.14 729.83 -3086.23         -226.05        .023* 
  West -1253.22 803.44 -2828.51          322.07        .119 
Marital Status  Married†      
  Separated -155.99 782.83 -1690.87 1378.88 .842 
  Never Married -1145.85 775.70 -2666.76  375.06 .140 
  Under 16 -3167.32 1429.39 -5969.92 -364.72 .027* 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .072, p< 0.05 
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Table 7 reports the regression analysis for total office-based expenditures in 
MSD's. Age group (66 years and above) was the significant predictor of total office-
based expenditures for MSD's. 
Table 8 reports the regression analysis for total prescription drug expenditures in 
MSD's.  Gender (male), age (41 to 65 years and 66 years and above), and census region 
of the US (Northeast) were significant predictors of total prescription drug expenditures 
for MSD's. 
Table 9 reports the regression analysis for total inpatient facility expenditures in 
MSD's.  Age (19 to 40 years), census region of the US (south and west), and marital 
status (under the age of 16 years) are significant predictors of total inpatient facility 
expenditures for MSD's. 
Table 10 reports the regression analysis for total emergency room expenditures in 
MSD's.  None of independent variables were significant predictors of total ER 
expenditures for MSD's. 
Table 11 reports the regression analysis for total outpatient facility expenditures 
in MSD's.  Age (41 to 65 years) and census region of the US (Midwest) were significant 
predictors of total outpatient facility expenditures for MSD's. 
Table 12 reports the regression analysis for total office-based chiropractor 
expenditures in MSD's.  Age (66 years and above), and marital status (separated) were 
significant predictors of total office-based chiropractors expenditures for MSD's. 
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Table 7. Predictors of the total office-based expenditures for MSD's in 2007 MEPS data 
 Model  B SE CI  Sig. 
(p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 804.15 501.18 -178.50 1786.80 .109 
  No MSD†      
        
Sex  Male -80.72 179.18 -432.04 270.60 .652 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 -161.43 475.33 -1092.43 770.55 .734 
  41 to 65 530.05 505.56 -461.19 1521.30 .295 
  66 and above 1348.59 540.29   289.24 2407.93 .013* 
        
Race  White†      
  Black -236.68 276.47 -778.74 305.39 .392 
  American Islanders 
& Native American 
 
-346.84 
 
889.93 
 
-2091.72 
 
1398.04 
 
.697 
  Asian -633.26 452.86 -1521.90 254.66 .162 
  Multiple race -354.19 653.05 -1634.61 926.23 .588 
        
Education Years  <12 years†      
  12 years -4.26 296.19 -585.00 576.48 .989 
  >12 years 440.17 281.23 -111.24 991.58 .118 
Census Region  Northeast†    
  Midwest 376.79 284.03 -180.10            933.69        .185 
  South -280.04 256.78 -783.51           223.42          .276  
  West -153.31 282.85 -707.90           401.27          .588  
Marital Status  Married†      
  Separated -464.82 275.59 -1004.46 76.08 .092 
  Never Married -362.07 273.08 -897.51 173.36 .185 
  Under 16 -305.45 503.24 -1292.12 681.20 .544 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .191, p< 0.05 
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Table 8. Predictors of the total prescription drug expenditures for MSD's in 2007 MEPS 
data 
 Model  B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 205.08 165.883 -120.16 530.32 .216 
  No MSD†      
        
Sex  Male 150.12 59.30 33.83 226.40 .011* 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 -45.99 157.32 -354.46 262.48 .770 
  41 to 65 868.54 167.33 358.45 1014.62 .000* 
  66 and above 1713.17 178.83 1362.54 2063.80 .000* 
        
Race  White†      
  Black -31.63 91.50 -211.5 147.78 .730 
  American Islanders 
& Native American 
-110.39 294.55 -687.92 467.14 .708 
  Asian -211.69 149.89 -505.59 82.19 .158 
  Multiple race -315.94 216.15 -739.75 107.85 .144 
        
Education Years  <12 years†      
  12 years 23.32 98.03 -168.89 215.51 .812 
  >12 years 120.62 93.08 -61.89 303.13 .195 
Census Region  Northeast†    
  Midwest 95.37 94.01 -88.95            279.69          .310 
  South 35.14 84.99 -131.50          210.78          .679  
  West 187.94 93.62 -371.50         -4.382           .045* 
Marital Status  Married†      
  Separated 84.86 91.21 -93.98 263.71 .352 
  Never Married 43.23 90.38 -133.98 220.46 .632 
  Under 16 -96.68 166.56 -423.25 229.89 .562 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .131, p< 0.05 
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Table 9. Predictors of the total inpatient facility expenditures in for MSD's 2007 MEPS 
data  
 Model  B SE CI  Sig. 
(p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 3949.42 903.29 2178.34 5720.90 .000* 
  No MSD†      
        
Sex  Male -440.78 322.95 -1073.99 192.42 .172 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 -1773.46 856.71 -3413.07 -53.57 .001* 
  41 to 65 -764.58 911.19 -2551.15 1021.99 .401 
  66 and above 790.48 973.98 -1118.26 2699.80 .417 
        
Race  White†      
  Black -184.07 911.18 -1161.07 792.91 .712 
  American Islanders 
& Native American 
-109.56 1603.97 -3254.4 3033.32 .946 
  Asian -972.62 816.22 -2572.91 627.73 .233 
  Multiple race 527.31 1177.02 -1780.46 2835.09 .654 
        
Education Years  <12 years†      
  12 years -392.83 533.84 -1439.53 653.83 .462 
  >12 years -87.41 506.88 -1081.25 906.42 .863 
Census Region  Northeast†    
  Midwest -480.68 511.92 -1844.41        523.03          .348 
  South -1356.50 462.81 -2263.93        -449.07         .003* 
  West -1198.53 509.80 -2198.09      -198.07         .002* 
Marital Status  Married†      
  Separated 182.58 496.72 -791.32 1156.50 .713 
  Never Married -927.74 492.20 -1892.80 37.30 .060 
  Under 16 -2344.68 906.86 -4123.00 -566.37 .001* 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .181, p< 0.05 
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Table 10. Predictors of the total ER facility expenditures for MSD's in 2007 MEPS data  
 Model  B SE CI  Sig. 
(p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 76.45 88.23 -96.53 249.5 .386 
  No MSD†      
        
Sex  Male 22.87 31.54 -38.97 84.72 .468 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 59.83 83.68 -104.20 223.90 .475 
  41 to 65 102.79 89.00 -71.71 277.30 .248 
  66 and above 74.38 95.11 -112.11 260.87 .782 
        
Race  White†      
  Black -10.49 48.67 -105.92 84.93 .829 
  American Islanders 
& Native American 
-84.59 156.67 -391.78 222.59 .589 
  Asian -56.48 79.72 -212.80 99.83 .479 
  Multiple race -60.78 114.96 -286.12 164.71 .598 
        
Education Years  <12 years†      
  12 years 15.01 52.14 -87.22 117.35 .773 
  >12 years -96.49 49.51 -193.57 .577 .051 
Census Region  Northeast†           
  Midwest 1.871 50.04 -96.17             99.91            .970 
  South 16.55 45.20 -72.07             105.19         .714         
  West 2.59 49.76 -95.04             100.22         .958 
Marital Status  Married†      
  Separated -3.42 48.51 -98.55 91.70 .944 
  Never Married 1.20 48.07 -93.05 95.47 .980 
  Under 16 -48.06 88.59 -221.76 125.64 .588 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .050, p< 0.05 
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Table 11. Predictors of the total outpatient facility expenditures in 2007 for MSD's 
 Model  B SE CI  Sig. (p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 106.81 122.38 -133.72 346.13 .386 
  No MSD†      
        
Sex  Male -23.69 43.75 -109.48 62.09 .588 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 -46.69 116.07 -274.22 180.93 .688 
  41 to 65 152.33 123.45 -89.71 394.38 .217 
  66 and above 372.57 131.93 113.89 631.25 .005* 
        
Race  White†      
  Black -66.28 67.51 -198.64 66.08 .326 
  American Islanders 
& Native American 
-73.75 217.31 -499.84 352.32 .734 
  Asian -167.62 110.58 -384.44 49.19 .130 
  Multiple race -7.57 159.46 -320.24 305.09 .962 
        
Education Years  <12 years†      
  12 years 44.03 72.32 -97.78 185.84 .543 
  >12 years 44.48 68.67 -90.16 179.13 .517 
        
Census Region  Northeast†    
  Midwest 136.798 69.358 .809           272.86         .049* 
  South -11.93 62.70 -134.93      110.94        .848 
  West 103.08 69.07 -32.34        238.50        .136 
Marital Status  Married†      
  Separated -64.98 67.29 -196.93 66.96 .334 
  Never Married -52.52 66.86 -183.27 78.20 .431 
  Under 16 -98.51 122.88 -339.44 142.41 .423 
† Reference group, B: Intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .091, p< 0.05               
 
 
 
 53 
 
 
Table 12. Predictors of the total office based chiropractor expenditures in 2007 for MSD's 
 Model  B SE CI  Sig. 
(p) 
Variables  Levels   Lower  Upper  
Bound Bound 
        
Presence of condition  MSD 26.06 26.83 -34.41 85.59 .382 
  No MSD†      
        
Sex  Male 2.79 10.66 -18.12 30.70 .794 
  Female†      
        
Age in years  0 to 18†      
  19 to 40 19.62 28.56 -35.84 75.12 .488 
  41 to 65 18.54 30.09 -40.06 70.99 .538 
  66 and above 79.14 32.16 16.10 142.61 .014* 
        
Race  White†      
  Black -13.48 16.45 -45.78 18.72 .413 
  American Islanders 
& Native American 
53.00 52.90 -50.80 156.88 .317 
  Asian 8.40 26.93 -61.20 44.34 .755 
  Multiple race -22.40 38.79 -98.61 58.44 .564 
        
Education Years  <12 years†      
  12 years -13.10 17.66 -47.62 21.44 .457 
  >12 years -9.88 16.45 -42.67 22.95 .566 
Census Region  Northeast†    
  Midwest -2.07 16.91 -35.22         31.22              .903 
  South -19.20 15.21 -49.10         10.72              .209 
  West 7.53 16.80 -25.41          40.21             .654  
Marital Status  Married†      
  Separated -33.74 16.43 -65.91 -1.57 .040* 
  Never Married -8.76 16.2 -40.63 8.23 .589 
  Under 16 -11.98 29.65 -70.71 46.70 .690 
† Reference group, B: intercept, SE: Standard Error, C.I: Confidence Interval, R Squared = .080, p< 0.05 
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Objective 5: To calculate a national estimate for the total incremental health care 
expenditures of MSD's compared to the non-MSD cohort. 
Incremental cost analysis is a decision-making technique used to determine the 
true cost difference between alternatives.  To calculate a national estimate for the 
incremental health care expenditures for treating MSD's, mean cost of individuals with 
non-MSD diagnosis was conducted.  A separate dataset of individuals with non-MSD 
was created and a linear regression model was run, similar to the MSD’s cohort.  The cost 
of treatment under different service categories was then calculated.  The incremental 
difference was calculated by subtracting the mean total cost per service category of non-
MSD from that of the MSD’s.  
The regression model used is as follows:  
Expenditure = Intercept + B1Presence of MSD + B2Age + B3Gender + B4Race + 
B5Marital Status + B6Census Region + B7Education years + E 
For a national estimate for each service category, the mean incremental difference was 
multiplied by the prevalence of MSD's cases for the year 2007: 
National Estimate = Incremental cost of MSD x Prevalence of MSD 
 The 2007 estimate was inflated to present day value (2011) by multiplying the 
2007 costs estimate with the 2011medical inflation rates reported by the BLS.
37
  The 
proportional increase in 2011 costs was calculated using the formula:  
2011 costs =2007 costs*(2011 index value /2007 index value) =2007 costs * 
(400.258/351.054) 
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 The prevalence of MSD's was assumed to be the same for 2007 and 2011.  Table 13 
presents the mean incremental cost difference and the national estimates for different 
service categories for both 2007 and 2011.  
  
 
5
6
 
Table 13. Incremental and national cost estimates for MSD's compared to non-MSD 
Service category                               Mean expenditures              Incremental cost    National Estimates 
         MSD's          Non-MSD  2007        Inflated 2011 value          2007            Inflated 2011 value 
Total health care expenditures             $91,121.41          $90,234.91            $886.49      $1010.74     $30.25 billion $35.61 billion  
Total emergency room expenditures           $493.50                $750.99                 $257.49*      $293.57  $8.71 billion $10.34 billion 
Total office-based chiropractor expenditures          $209.97          $603.23           $393.27*     $448.32  $13.40 billion $15.79 billion 
Total office-based expenditures           $16,338.80          $16,834.81           $496.01*       $565.45  $16.92 billion $19.92 billion 
Total prescription drug expenditures          $26,384.35           $25,651.44           $732.91                $835.51  $25.01 billion $29.43 billion 
Total outpatient facility expenditures          $3,573.41          $5,252.28           $1678.87*      $1913.91 $57.29 billion $67.43 billion 
Total inpatient facility expenditures           $33,461.85           $30,798.62           $2663.22      $3036.06 $90.80 billion  $106.97 billion 
 The national prevalence of MSD's in 2007 was 11.3%. The prevalence rate was assumed to be the same in 2011. 
US Population in 2007 = 302,000,000 
US Population in 2011= 311,811,000 
* Negative increment for MSD's 
Inflated value calculated by multiplying the costs with a ratio of 2011 index value (400.258) and 2007 index value (351.054) 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSIONS 
 
This study utilized the HC and the MPC from the 2007 MEPS data to study the 
demographics, prevalence estimates, and cost estimates of MSD’s.  Specifically, the 
study estimated the total health care expenditures in MSD’s  and the costs of different 
service categories including total inpatient facility expenditures, total outpatient facility 
expenditures, total prescription drug expenditures, total office-based chiropractors 
expenditures, total office based expenditures, and total emergency room facility 
expenditures.  The study also estimated the incremental costs of MSD’s compared to non-
MSD and identified the predictors associated with these cost estimates. 
In 2007 MEPS data, 94,246 individuals were surveyed and this translated into a 
weighted national population of 301,309,149.  Of the total weighted population, 11.3% 
had a primary diagnosis of MSD's.  As per our study, in 2007 approximately 34.8 million 
people suffered from a primary musculoskeletal condition.  Since MEPS data only 
provides primary diagnoses, this prevalence rate is an underestimate and will likely be 
higher if both primary and secondary diagnosis for MSD's are considered.   
Very few studies have reported the prevalence data for MSD’s in the US. Yelin et 
al. (1996) reported that 4,161 individuals (unweighted) had a primary or secondary 
musculoskeletal conditions with  53.935 million individuals nationwide (20.1% of the 
population) reporting at least one musculoskeletal condition.
32
  Another study using the  
2004-2005 National Health Interview Survey (NHIS) estimated a total of 110.8 million 
 58 
 
 
individuals with a primary or a secondary musculoskeletal condition.
3
  In yet another 
MEPS data study, the prevalence of MSD in the US population was reported as 10.6% in 
2006.
39
 
Based on the data from the last decade, there seems to be an upward trend in the 
prevalence of MSD’s in the US.  One of the most commonly cited reason for this trend is 
the increase in the aging population in the US.
3
  Other reasons that are responsible for the 
increase in prevalence include the burden of other chronic disorders, life style changes, 
and increasing life expectancy.
3
  Contrary to the popular belief that MSD’s are common 
in aging population; in this study, high prevalence was also seen in the age categories of 
0-18 years and 19-40 years.  Some potential explanations for the increased prevalence in 
these age groups could be due to the nature of work activities that require physical stress 
(e.g., sports, heavy labor intensive jobs).
3  
Thus, the prevalence of MSD's in the elderly 
seem to be a chronic condition and is also prevalent in the young adults, although as an 
acute condition. 
The demographic analysis of the 2007 MEPS data revealed a higher prevalence of 
MSD’s in females (52.1%) compared to the males (47.9%).  This finding is consistent 
with those reported by other studies.  Wijnhoven et al. (2006) presented an overview of 
gender differences in musculoskeletal pain and presented data obtained from two general 
population-based prospective surveys administered in a Dutch population.  Study 
reported that females experienced MSD’s at a higher rate (45%) than males (39%).39  
Based on epidemiologic data, females tend to have  higher incidences of rheumatic 
conditions than males.
39
  A number of reasons are cited for the higher  prevalence in 
females including hormonal changes, genetic differences, and lifestyle differences 
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between the two genders.  Females experience both exogenous changes in hormonal 
levels (e.g., due to oral contraceptive pill) and endogenous changes (particularly related 
to menstruation and pregnancy history).  The genetic influence could either be direct i.e., 
influence of genes on sex chromosomes or indirect i.e., microchimerism.
40
  
The data was analyzed to study the prevalence of MSD’s by the census region of 
the US.  A majority of individuals with MSD’s were from the South (38.6%) followed by 
the West (26.9%), Midwest (20.4%), and Northeast (14%).  A number of reasons can 
possibly explain this trend.  The higher obesity rates in the southern part of the US are 
considered a major contributor to the increased prevalence of MSD's in this region.
41
  
Genetic reasons are also cited for the increased incidence of MSD's.
42
  Hundreds of genes 
are involved in making proteins that protect muscle fibers from damage.  Muscular 
dystrophy leading to MSD's occurs when one of these genes is defective.  Each form of 
muscular dystrophy is caused by a genetic mutation that's particular to that type of the 
disease.  Many of these mutations are inherited, but some occur spontaneously in the 
mother's egg or in the developing embryo.
42
  Environmental influence is another major 
factor responsible for MSD's cases.  Workers in the colder region have high prevalence of 
MSD's, especially of the lower back and shoulders.  Cold weather has shown to increase 
the risk of muscle strain resulting in tense muscle tissues, which are susceptible to 
injuries.
43
 
In the literature, MSD’s are commonly reported as the disease of the “Whites” 
since the prevalence is always higher in Whites than in other races.
44  
Consistent results 
were seen in our study (Whites -75.1%; Blacks - 17.1%) although we have to be careful 
in drawing our conclusions based on the surveyed individuals given the over sampling of 
 60 
 
 
Whites in 2007 MEPS data.  However, since the data was adjusted with sample weights, 
we are confident that the weighted results are much more reflective of the national 
prevalence data.  
The data was analyzed to study the prevalence of MSD’s by marital status.  
Majority of the individuals with MSD’s were married (38.2%) and this observation can 
be explained by the fact that married workers have several non-occupational 
responsibilities such as cleaning, washing, taking care of their spouse and children, to 
name a few, which exposes them to more ergonomic stressors than those who are not 
married.
45
 
The study also analyzed the prevalence of MSD's based on the years of education 
of an individual.  The study results are similar to the previous findings that individuals 
with 12 years or less of education had the highest prevalence of MSD's.
46
  This is 
primarily due to the fact that individuals with less education are less aware of the MSD's 
and the factors that lead to MSD's.  Also, poor understanding of the disease and its 
processes has been observed in individuals who are less educated.
46
  Additionally, those 
with less education are more likely to be involved in labor-intensive jobs.
47
 
The study estimated the mean total health care expenditures at $91,121.41 with an 
estimated incremental societal burden of $30.25 billion in the US in 2007.  The high costs 
of MSD’s could be attributed to the growing number of aging population and younger 
individuals affected by the condition and the use of biologics in the treatment of MSD's.  
For treating individuals with MSD's, both invasive and non-invasive procedures are 
conducted.  Some procedures like hip replacements or joint surgeries are extensive and 
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involve extended care at a live-in facility.  Also, the annual medication expenditures for 
treatment of RA and AS with the new biologic drugs can be as high as $15,000 - $20,000 
per patient which significantly increases the costs burden of the disease.
40
  Additionally, 
if individuals with both primary and secondary diagnosis of MSD’s condition are 
considered and the indirect cost (e.g., loss in productivity) is calculated, the overall 
burden of MSD’s on the society will be enormous. 
The study compared the different service category costs in MSD’s with those of 
non-MSD.  From our analysis, we found that there is a significant burden of MSD's due 
to the inpatient expenses.  Analysis suggested that there was a mean $2,663.20 
incremental burden of MSD over non-MSD individuals.  Taking into account the total US 
population for the year 2011, the overall annual expenditures due to inpatient facility 
expenditure of the MSD's in the US was approximately $106.97 billion.  A study by 
Osborne et al. suggested that MSD's was responsible for the 6th largest inpatient visits in 
the US followed by renal dialysis, general surgery, obstetrics, gastroenterology, and 
general medicine.
48 
 As suggested earlier, a possible reason for increased inpatient 
expenditures could be due to the use of invasive and non-invasive procedures such as 
joint surgeries, corticosteroid injections, anesthetic injections, and dry needling etc.
49
  
Secondly, with the increase in aging population, there is an increased utilization of these 
procedures, which leads to increased total inpatient facility expenditures for MSD's.  
Preventive steps such as early detection of the disease and screening programs, laboratory 
tests like alkaline phosphatase and RA factor test are needed to limit the inpatient facility 
cost as the number of individuals with MSD’s is increasing and the demand for inpatient 
services are growing.  For example, individuals should be regularly screened using 
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techniques like x-rays, ultrasound, and MRI  for symptoms related to MSD's and should 
be treated at a level where inpatient procedures are not required.  These screening 
procedures, although expensive, have been very effective in lowering the cost of 
treatment for disease conditions like diabetes mellitus in the long run.
28
  For example, in 
diabetes, glycosylated hemoglobin (HbA1c), foot ulcer, smoking status, and retinopathy 
are assessed on a regular basis which helps control the disease and also keeps the disease 
management costs in control. 
Study results also showed that the mean expenses for total outpatient facility for a 
non-MSD were higher ($1,678.87) than the mean expenses for MSD's.  This is consistent 
with previous studies that reported that the total outpatient facility charges were higher 
for non-MSD compared to MSD's.
44
  Individuals suffering from MSD's require inpatient 
care and do not use outpatient care as much due to the nature of the disease condition. 
  Prescription drug utilization was higher in MSD's.  Kaiser Foundation reported 
that around 10% of the total health care costs was due to prescription drugs alone.
50
  It 
was suggested that the overall prescription costs has decreased, although there was an 
increase in the prescription costs in chronic conditions, especially in the aging population.  
Our study findings are consistent with those reported by Kaiser Foundation and 
demonstrates an increasing prescription drug utilization in MSD's.
46
  Another reason for 
the increased prescription drugs costs in MSD’s is the enormous costs of the new 
biological treatments that was introduced in the early 2000.  
Study result indicated that office-based facility expenditures are lower for MSD's 
as compared to non-MSD.  Office-based services include any infusion expenses and other 
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services administered to the patient in the physician's office.  For example, biologics such 
as Remicade® is administered as an infusion in a physician’s office.  These expenditures 
are lower for MSD's due to the fact that MSD's require more inpatient care and mostly 
use prescription drugs to control their symptoms.   
Studies have shown that chiropractic care is a cost-effective alternative to the 
management of musculoskeletal conditions.
51
  Chiropractor care is required in the post-
operative rehabilitation care and also in treatments which are non-invasive in nature such 
as OssaTron Orthotripsy method.  Results indicated that there is a higher office-based 
chiropractor cost for non-MSD due to injuries resulting from slips, trips, falls, or similar 
accidents which are not included under MSD's.  Similar to chiropractor expenditures, 
study results indicated that total emergency room facility for MSD's was lower ($257.49) 
compared to non-MSD.  Those with MSD's seldom have disease flare ups which require 
them to go to emergency room.  Most patients get relief from their relapses by taking 
their medications or by visiting the physician.  Also, severe cases most likely use the 
inpatient facility than the emergency facility. 
The national estimates for each service category were compared to previous 
estimates for the different service category expenditures.  There has been a significant 
increase across the different service category costs.  Inpatient service expenditures, 
prescription drug expenditures, and total health care expenditures have increased 
significantly over the last decade and a half.
24
  On inflating these expenditures to the 
present day estimates (2011 value), the study confirms the significant incremental burden 
of MSD’s on the health care system in the US compared to non-MSD.     
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Conclusions  
There is a significant burden of the MSD's on the US health care system.  The 
prevalence of MSD in the US was estimated at 11.3%.  Approximately, 34,888,246 
people were affected by at least one MSD condition in 2007.  A majority of individuals 
affected by MSD's were whites and were in the southern region of the US.  Given the 
high prevalence of MSD, the annual incremental direct medical expenditures for the 
treatment of MSD's was estimated at $30.25 billion (2007 value) and $35.61 billion 
(2011 value). 
 The annual incremental total health care expenditures associated with MSD's over 
non-MSD were $886.49 per person, an increase from $534.5 per person in the year 
2006.
39
  There was a significant cost burden of the MSD's on some health care services.  
This cost is still an underestimate of the true cost and could be higher if secondary 
diagnosis and indirect costs associated with MSD's are included in the analysis.   
 
Study Implications  
 The present study improves upon some previous national estimates of MSD’s and 
also estimated the major domains of healthcare utilization with predictors of these costs.  
The study findings are important for several reasons.  The new healthcare reform bill 
with increased coverage for uninsured population coupled with an increase in aging 
population and increase in the prevalence of MSD’s could potentially result in increased 
health care recourse utilization.  Thus, there is a need to introduce strategies at the grass 
root level which will not only decrease the burden of MSD's on the health care system 
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but also reduce the overall costs associated with the disease.  Strategies like disease 
screening and increased health literacy will be helpful in decreasing the overall disease 
prevalence by early detection and treatment. As discussed earlier, screening techniques 
such as the use of x-rays and ultrasound can be helpful in controlling the increase in 
disease severity in a timely manner.  There have been increased cases of MSD's among 
individuals less than 18 years of age.  There is a need to implement programs like health 
awareness among children about the causes of MSD's.  For reducing resource utilization 
among elderly individuals suffering from chronic conditions, home health model could be 
implemented, that will help in decreasing the emergency room and inpatient facility 
expenses, and would also provide better care to the individuals. 
This study will help the managed care organizations and payers such as Medicare in 
understanding the increased burden of MSD's.  The systematic assessment of MSD's and 
their associated incremental costs to the society is essential in increasing the awareness of 
decision makers to implement intervention strategies that are effective in lowering the 
disease incidence and in reducing the overall cost of disease management. The 
implementation of   disease management programs like home health and screening for 
early disease detection and the use of cost-effective treatments will help payers control 
the rising costs of MSDs, including the cost of MSD-related prescription drugs.   
 
Study Limitations  
The present study has some limitations: First, the limitations associated with a 
retrospective database are applicable to this study.  Some of these limitations include 
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dependency on previously recorded data in the database, whose quality may be limited by 
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality, 
and confounding factors.  Second, we identified individuals with MSD's and non-MSD 
based on the self-reported medical conditions of the survey respondents.  Based on the 
accuracy of the self-reported data, there is a possibility of f over-estimating or under-
estimating disease prevalence.  Third, the analysis only included direct medical expenses.  
Indirect cost such as loss of productivity transportation expenses, lost wages among 
family members, caregiver burden, etc., were not included in the estimation of the overall 
expenditures calculation.  Fourth, the study included only patients with the primary 
diagnosis of MSD's, since MEPS does not provide secondary diagnosis.  Finally, the low 
R-squared that is observed in the regression analyses should be considered.  Non-
experimental cross-sectional studies obtained from a panel or longitudinal data generally 
present a low R-squared in the estimation of the DV.  The reason for the low R-squared 
may stem from the nature of the epidemiological data (longitudinal or panel) i.e.,  it is a 
combination of cross-sectional and time-series datasets, and the R-squared reported from 
an analysis using this type of data is rather “cross sectional-like”.  For instance, if one 
compares person A’s outcomes with his/her own outcomes at different times (time-series) 
one can certainly explain much of the variation with just a few variables.  However, if 
one compares person A’s outcomes with person B’s outcomes (cross-sectional) those 
same few variables will explain less, if any, of the variation.  Thus, a cause for concern 
on a low R-squared depends on the type of dataset employed and the model. 
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